AI assistant
Altimmune, Inc. — Director's Dealing 2024
Feb 2, 2024
33207_dirs_2024-02-01_2487a7be-33bd-4f46-b8ba-af4e9d280ecb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2024-01-31
Reporting Person: Jordt Raymond M (Chief Business Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-31 | Common Stock, par value $0.0001 | A | 5030 | $2.69 | Acquired | 13743 | Direct |
Footnotes
F1: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2023 through January 31, 2024.
F2: In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2023.
F3: The Issuer withheld 2,494 shares to cover taxes associated with the vesting of RSU on January 1, 2024 instead of the 2,503 shares reported as withheld on the individual's Form 4 filed on January 4, 2024. The updated total is reflective of the foregoing correction.